Atlas Trials

ADC Therapeutics S.A.

21 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch ADC Therapeutics S.A.

RecordFirmDate
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) (NCT05660395)ADC Therapeutics S.A.2023-07-28
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors (NCT05389462)ADC Therapeutics S.A.2022-07-13
A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (NCT05144009)ADC Therapeutics S.A.2022-06-21
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) (NCT04970901)ADC Therapeutics S.A.2022-06-17
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) (NCT04974996)ADC Therapeutics S.A.2022-02-01
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors (NCT04972981)ADC Therapeutics S.A.2021-09-09
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT04384484)ADC Therapeutics S.A.2020-09-16
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT04052997)ADC Therapeutics S.A.2019-09-13
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma (NCT03685344)ADC Therapeutics S.A.2019-02-04
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma (NCT03684694)ADC Therapeutics S.A.2018-12-01
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (NCT03621982)ADC Therapeutics S.A.2018-11-09
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT03589469)ADC Therapeutics S.A.2018-08-01

Track ADC Therapeutics S.A. automatically

Every clearance here is in the API, with alerts when new ones post.